Sitimagene ceradenovec, a gene therapeutic for the treatment of glioma.

Abstract

Ark Therapeutics Group plc is developing sitimagene ceradenovec, a herpes simplex virus thymidine kinase/ganciclovir gene therapy utilizing an adenoviral vector, for the potential treatment of glioma. Sitimagene ceradenovec is currently undergoing a phase III clinical trial in malignant glioma patients.

• Authors: Nejat Düzgünes
• Journal: Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 10 Issue 2 Pg. 187-95 (Apr 2008) ISSN: 1464-8431 [Print] England
• PMID: 18386231 (Publication Type: Journal Article)

Chemical References

• Thymidine Kinase
• sitimagene ceradenovec

Topics

• Animals
• Brain Neoplasms (therapy)
• Contraindications
• Drug Evaluation, Preclinical
• Genetic Therapy
• Glioma (therapy)
• Humans
• Structure-Activity Relationship
• Thymidine Kinase (pharmacokinetics, therapeutic use)